Table 1 Cohort summary statistics.
From: Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease
Cohort | PD patients Post-QC (n) | Follow up, years | No.(%) LiD | No.(%) left-censored | No.(%) male | Time to midpoint event (mean ± sd) | AAO, years (mean ± sd) | AAB, years (mean ± sd) | Disease duration at baseline from onset, years (mean ± sd) | MDS-UPDRS part III at baseline (mean ± sd) | Levodopa dose at baseline (mean ± sd) |
|---|---|---|---|---|---|---|---|---|---|---|---|
Tracking Parkinson’s | 1478 | 7.5 | 177 (12) | 16 (1) | 945 (64.23) | 7.47 (2.18) | 64.43 (9.16) | 67.29 (9) | 2.86 (1.58) | 22.36 (11.69) | 217 (197) |
OPDC | 705 | 9.0 | 92 (13) | 8 (0.8) | 451 (64) | 7.87 (2.87) | 64.35 (9.47) | 67.21 (9.26) | 2.85 (1.70) | 26.27 (10.82) | 280 (205) |
PPMI | 283 | 9.0 | 82 (21) | 0 (0) | 259 (66) | 8.28 (2.27) | 60.16 (9.93) | 62.08 (9.78) | 1.92 (1.30) | 21.38 (9.10) | 0 (0) |
PD STAT | 77 | 2.0 | 10 (13) | 4 (4.9) | 48 (62) | 8.77 (2.83) | 57.23 (8.7) | 64.84 (9.24) | 7.61 (1.73) | 28.86 (11.61) | NA |
PDBP | 241 | 5.0 | 33 (14) | 16 (6) | 149 (62) | 5.93 (2.66) | NA | 64.58 (9.3) | 2.85 (2.51) | 20.9 (11.11) | 414 (207) |
